Eli Lilly Begins Construction on $6.5 Billion Houston Facility

Industry Pulse News Desk · 2026-09-24

Construction has begun on a new $6.5 billion pharmaceutical manufacturing facility in Houston to boost domestic production capabilities.

Eli Lilly and Company has broken ground on a $6.5 billion manufacturing site in Houston, marking one of the largest single investments in pharmaceutical production infrastructure in the region. The project is designed to significantly expand the company's domestic manufacturing capacity for active pharmaceutical ingredients and finished medicine products.

Engineering and construction firm Bechtel has been selected to support the development of the expansive industrial complex. The project will involve the construction of advanced processing suites, quality control laboratories, and automated packaging facilities across the Houston campus.

The new facility aligns with broader efforts within the healthcare sector to strengthen domestic supply chains and reduce reliance on overseas manufacturing. Once fully operational, the plant is expected to generate thousands of direct and indirect jobs, including roles in chemical engineering, site operations, and facility maintenance.

Construction activities are expected to proceed over the next several years, with phased commissioning planned as individual processing units are completed. State and local economic development officials have cited the investment as a major catalyst for the regional life sciences sector.

Eli Lilly continues to expand its global production network in response to rising demand for specialized biopharmaceutical treatments. Further operational timelines and hiring details are anticipated to be released as site development progresses.